Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Septerna, Inc.

NASDAQ: SEPN · Life Sciences · 6 alerts · CIK 1984086

Share price
$41.67Close, Nov 16
Market cap
$1.98B
Shares outstanding
47.55MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Septerna, Inc. filings on SEC EDGAR ↗

4:05 PM ET 8-K
Financial Results

Septerna Financial Results

Septerna reported third quarter 2026 financial results and provided a business update, highlighting a cash position of $565.2 million which is expected to fund operations into mid-2029. The company expects Phase 1 clinical data for its PTH1R agonist SEP-479 in Q1 2027 and plans to initiate a Phase 1 trial for its newly selected Graves’ disease candidate, SEP-204, in the same period.

Term
Q3 2026

“We are building momentum across our portfolio, with an upcoming important clinical milestone for SEP-479, our oral PTH1R agonist for hypoparathyroidism, and the selection of SEP-204 as our oral TSHR NAM development candidate for Graves’ disease and thyroid eye disease.”

Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder

“With Phase 1 data for SEP-479 and the initiation a Phase 1 trial of SEP-204 expected in the first quarter of 2027, we are moving closer to realizing our ambition to translate our GPCR expertise into differentiated oral medicines for patients with significant unmet needs.”

Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.